)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
BioMarin Pharmaceutical (BMRN) investor relations material
BioMarin Pharmaceutical M&A Announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A Announcement summary19 Dec, 2025
Deal rationale and strategic fit
Expands leadership in rare diseases by adding two high-growth, marketed therapies for Fabry and Pompe diseases, leveraging a global commercial footprint and in-house manufacturing to reach more patients.
Both companies share a mission-driven culture focused on innovative therapies for genetically defined rare diseases and a commitment to global patient access.
The deal is positioned as a seamless, strategic fit with complementary capabilities and supports capital allocation strategy to diversify and maximize growth drivers.
Financial terms and conditions
All-cash transaction at $14.50 per share, valuing the deal at $4.8 billion and representing a 33% premium to the prior closing price.
Premiums of 46% and 58% to the 30- and 60-day volume-weighted average prices, respectively.
Financed through cash on hand and $3.7 billion in non-convertible debt; not subject to financing conditions.
Unanimous approval by both companies' Boards of Directors.
Pro forma gross leverage at closing projected between 3.0x-3.5x, with a target of under 2.5x within two years post-close.
Synergies and expected cost savings
Immediate revenue contribution and increased long-term CAGR, diversifying revenue mix and driving efficiencies aligned with margin expansion.
Expected to be accretive to non-GAAP diluted EPS within 12 months and substantially accretive from 2027.
Integration expected to increase net profits and cash flows over time, with a focus on maintaining and building Amicus’s capabilities.
Detail deleveraging strategy post-close
Target markets for Galafold/Pombiliti expansion?
DMX-200's strategic role in BioMarin's pipeline?
Initial gross leverage and deleveraging plan?
How to accelerate Pompe's early launch trajectory?
Galafold's growth strategy post-2037 IP expiry?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioMarin Pharmaceutical earnings date
Q4 202518 Feb, 2026
Next BioMarin Pharmaceutical earnings date
Q4 202518 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. Its research and product development efforts target conditions with limited treatment options, primarily in the fields of enzyme replacement and gene therapy. The company serves healthcare providers and patients worldwide through approved treatments and scientific initiatives. The company is headquartered in San Rafael, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage